No abstract available
Keywords:
Altoprev; Colestid; Crestor; Ezetrol; Flolipid; Lescol; Lipitor; Livolo; Lodalis; Lopid; Nexletol; Nexlizet; Olestyr; Praluent; Pravachol; Prevalite; Repatha; Vascepa; Vytorin; Welchol; Zetia; Zocor; Zypitamag; adverse effects; alirocumab; atorvastatin; bempedoic acid; cholesterol; cholestyramine; colesevelam; colestipol; dosage; drug interactions; efficacy; evolocumab; ezetimibe; fenofibrate; fluvastatin; gemfibrozil; icosapent ethyl; lactation; lovastatin; niacin; pitavastatin; pravastatin; pregnancy; rosuvastatin; safety; simvastatin; statins.
MeSH terms
-
ATP Citrate (pro-S)-Lyase / antagonists & inhibitors
-
Anticholesteremic Agents / adverse effects
-
Anticholesteremic Agents / pharmacology
-
Anticholesteremic Agents / therapeutic use*
-
Cholesterol, LDL / blood*
-
Dicarboxylic Acids / adverse effects
-
Dicarboxylic Acids / pharmacology
-
Dicarboxylic Acids / therapeutic use*
-
Fatty Acids / adverse effects
-
Fatty Acids / pharmacology
-
Fatty Acids / therapeutic use*
-
Humans
-
Hypercholesterolemia / drug therapy*
-
Hypercholesterolemia / pathology
Substances
-
Anticholesteremic Agents
-
Cholesterol, LDL
-
Dicarboxylic Acids
-
Fatty Acids
-
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
-
ATP Citrate (pro-S)-Lyase